NCX 470 是 Nicox 的主要临床产品候选者,是一种新型的、可能是同类最佳的、一氧化氮 (NO) 捐赠前列腺素模拟滴眼液。 Mont Blanc 是一项多区域、双盲、为期 3 个月的平行组试验,评估 NCX 470 滴眼液 0.1% 与latanoprost ophthalmic solution(拉坦前列素滴眼液) 0.005% 的疗效和安全性。拉坦前列素是开角型青光眼...
Purpose : NCX 470 is a nitric oxide (NO)-donating prostaglandin analog in development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This work evaluated the ocular hemodynamic effects and neuroprotective activity of NCX 470 in rabbits....
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2019 Apr;176(8):1079-1089. [2]. Impagnatiello F, et al. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models....
Les deux doses de la solution ophtalmique NCX 470 évaluées, 0,065 % et 0,1 %, ont réduit la pression intraoculaire davantage que le comparateur, latanoprost solution ophtalmique 0,005 % La concentration de 0,1 % de NCX 470 a été retenue pour la suite de l’étude Mont Blanc ...
? Keyboard Word / Article Starts with Ends with Text EnglishEspañolDeutschFrançaisItalianoالعربية中文简体PolskiPortuguêsNederlandsNorskΕλληνικήРусскийTürkçeאנגלית 9 RegisterLog in Sign up with one click: ...
NCX 470 可用于研究血管性高血压和青光眼的研究。 研究领域:GPCR/G Protein 作用靶点:Prostaglandin Receptor In Vivo: NCX 470 shows a better intraocular pressure-lowering efficacy than that of equimolar doses of bimatoprost in well-established animal models of glaucoma and ocular hypertension.NCX 470 ...
Glaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseases Nicox focused on continued Phase 3 development of lead drug-candidate, NCX 470 September 23rd, 2024 – release...
NCX 470 滴眼液的适应症是开角型青光眼或高眼压症。 此药物由Nicox Ophthalmics, Inc./ Siegfried Irvine/ 欧康维视生物医药(上海)有限公司生产并提出实验申请,[实验的目的] 本研究的主要目的是证明NCX 470滴眼液(0.1%)QD不劣于拉坦前列素滴眼液(0.005%)QD ...
glaucomanitric oxidePurpose: To determine NCX 470 (0.1%) and Lumigan (bimatoprost ophthalmic solution, 0.01%—LUM) intraocular pressure (IOP)-lowering activity after single or repeated (5 days) dosing along with changes in aqueous humor (AH) dynamics.Methods: Ocular hypotensive act...
Glaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseases Nicox focused on continued Phase 3 development of lead drug-candidate, NCX 470 September 23rd, 2024 – release at 7:30 am CET ...